Elsevier

Peptides

Volume 29, Issue 5, May 2008, Pages 735-742
Peptides

Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: Relevance to function

https://doi.org/10.1016/j.peptides.2007.08.021Get rights and content

Abstract

We have examined whether differential expression of UT receptors in cardiovascular tissues from rats and humans may account for the diverse vascular actions reported for urotensin-II. We found UT immunoreactivity ubiquitously expressed in arterial and venous smooth muscle and cardiomyocytes in both species, however, compared to human, levels of UT immunoreactivity in rat vascular endothelial cells was below the level for detection. In rat skeletal muscle cells UT receptor localized to the sarcolemma, a pattern comparable to that for isoforms of nitric oxide synthase suggesting that urotensin-II mediated hindquarter vasodilatation may involve release of nitric oxide from skeletal muscle fibers.

Introduction

Urotensin-II (U-II) is a 12 amino acid peptide that was originally discovered in the urophysis of the teleost fish, Gillichthys mirabilis [35]. A gene encoding a human form of U-II was subsequently cloned [9] and the G protein-coupled receptor UT, a human homologue of the rat orphan receptor GPR14/SENR [31], [41], identified as the endogenous receptor for the human undecapeptide U-II (hU-II) [2]. In fish, U-II has a variety of endocrine functions and has been demonstrated to constrict fish smooth muscle [4], [35]. The fish peptide, containing the characteristic cyclic hexapeptide that is essential for the biological activity of U-II from all species [28], also shows vasoconstrictor properties in the blood vessels from mammals [16], [20], suggesting an evolutionary conserved role for this receptor system in the regulation of cardiovascular function. This is supported by the discovery of genes for UT and U-II in a number of mammalian and non-mammalian species including the flounder [26], frog [9], mouse [8], pig [33] and cat [3].

Messenger RNA (mRNA) encoding both UT [2], [11], [25] and U-II [2], [8], [12] is abundantly expressed in the cardiovascular tissue of rats and humans, with the highest levels of UT mRNA expression observed, unexpectedly, in skeletal muscle [11]. Accordingly, UT receptors have been identified, using radioligand binding, in human myocardium, blood vessels and skeletal muscle [29] as well as in rat blood vessels [20], [29]. U-II has been reported to be the most potent vasoconstrictor of mammalian blood vessels discovered [2] and also elicits endothelium-dependent vasodilatation. Localization of the peptide to vascular endothelial cells of healthy [2], [30] and diseased [12], [30] human blood vessels using immunocytochemistry suggest that U-II acts as an autocrine/paracrine mediator at least in the vasculature. Whether U-II induces vasoconstriction or vasodilatation appears to depend on the species (for example, U-II contracts human arteries and veins in vitro [29] but is arterioselective in monkey [2]) and the vascular bed investigated and on the presence or absence of a functional endothelium, for review see refs. [10], [28]. In the conscious rat, in vivo, the effect of infused U-II is an increase in heart rate, blood pressure and vascular conductance in the hindquarters, effects attenuated by the nitric oxide synthase (NOS) inhibitor L-NAME and the non-selective cyclo-oxygenase inhibitor indomethacin [15].

To examine whether differential expression of UT receptors in cardiovascular tissues from rats and humans may account for the diversity of vascular actions observed for U-II we have investigated the distribution of UT in a representative panel of rat tissues using standard immunocytochemistry. In skeletal muscle, additional experiments were performed to localize NOS isoforms and the endothelial cell marker von Willebrand factor for comparison. We employed fluorescent double labeling confocal microscopy to identify the specific cell types expressing UT in rat compared to human tissue and in human umbilical vein endothelial cells (HUVECs) to establish morphological evidence for the involvement of either the synthetic or secretory pathways in the production and release of endothelial U-II.

Section snippets

Materials

Rabbit anti-UT receptor (human) antibody was purchased from Lifespan Biosciences (Seattle, WA, USA). UT receptor blocking peptide was from MBL International Corporation (Woburn, MA, USA). Human urotensin-II and rabbit anti-human urotensin-II antibody were from Peptide Institute Inc. (Osaka, Japan). Mouse anti-NOS I (brain/neuronal NOS), anti-NOS III (endothelial NOS) and anti-NOS II (inducible NOS) monoclonal antibodies were from Affiniti Research Products Ltd. (Exeter, UK). Mouse anti-human

Immunocytochemistry

In rat heart, UT-LI was localized to cardiomyocytes of the left and right atrium and ventricle (Fig. 2A). UT-LI was also detected in hindquarter skeletal muscle and in smooth muscle cells forming the medial layer of blood vessels from the rat heart, hindquarters (Fig. 2B), kidney (Fig. 2C) and mesentery (Fig. 2D and H). UT-LI was absent or below the level of detection in endothelial cells lining these blood vessels (Fig. 2H). In rat skeletal muscle UT-LI appeared to localize to regions of the

Discussion

U-II has been shown, in vitro and in vivo, to contract [5], [23], [27], [28], [29], [30], [34] and relax [39] human arteries and veins and to elicit effects on human heart [36] actions presumed to be due to stimulation of UT receptors. We have now substantiated this hypothesis by demonstrating the presence of UT-LI in human cardiovascular tissues, confirming the ubiquitous localization of UT receptor protein to vascular smooth muscle and endothelial cells of human large and small diameter

Acknowledgments

Supported by grants from the British Heart Foundation, Cambridge European and Isaac Newton Trusts. We thank the Consultant and theatre staff of Papworth Hospital for collection of human tissues. HUVECs were a kind gift from Dr. Jun Wang (Department of Medicine, University of Cambridge).

References (42)

  • T. Mayadas et al.

    von Willebrand factor biosynthesis and partitioning between constitutive and regulated pathways of secretion after thrombin stimulation

    Blood

    (1989)
  • M. Mori et al.

    Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14)

    Biochem Biophys Res Commun

    (1999)
  • M. Tal et al.

    A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia

    Biochem Biophys Res Commun

    (1995)
  • R.S. Ames et al.

    Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

    Nature

    (1999)
  • D.J. Behm et al.

    Urotensin-II: a novel systemic hypertensive factor in the cat

    Naunyn Schmiedebergs Arch Pharmacol

    (2004)
  • F. Böhm et al.

    Urotensin II evokes potent vasoconstriction in human in vivo

    Br J Pharmacol

    (2002)
  • F.E. Bottrill et al.

    Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries

    Br J Pharmaol

    (2000)
  • P.S. Clifford et al.

    Vasodilatory mechanisms in contracting skeletal muscle

    J Appl Physiol

    (2004)
  • Y. Coulouarn et al.

    Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord

    Proc Natl Acad Sci USA

    (1998)
  • S.A. Douglas et al.

    Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines

    Br J Pharmacol

    (2004)
  • S.M. Gardiner et al.

    Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response

    Br J Pharmacol

    (2004)
  • Cited by (30)

    • Characterization of four urotensin II receptors (UTS2Rs) in chickens

      2021, Peptides
      Citation Excerpt :

      UTS2R is reported to be widely expressed in the CNS including the hippocampus, amygdala, pineal gland, hypothalamus, and cerebellum, particularly abundant in the brain stem and spinal cord in rodents [19,31,32]. Apart from the CNS, UTS2R is widely expressed in peripheral organs, such as the heart, lung, skeletal muscle, and endocrine system, notably in the pancreas and adrenal gland in humans [25,33–36]. Unlike that in mammals, five UTS2R genes, named UTS2R1, UTS2R2, UTS2R3, UTS2R4, and UTS2R5 have been identified or predicted to exist in non-mammalian vertebrates.

    • Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice

      2020, European Journal of Pharmacology
      Citation Excerpt :

      UT was originally identified as an orphan GPCR receptor; GPR-14 (Vergura et al., 2004). UT gene is widely expressed in the central nervous system (CNS) and in peripheral tissues including retina, heart, vascular bed, lung, kidney, adrenal medulla, and skeletal muscle (Hunt et al., 2010; Maguire et al., 2008). Various studies have revealed the increased expression of U-II and its receptor UT in the failing hearts and renal diseases (Ng et al., 2002; Douglas et al., 2002; Bousette et al., 2006a,b; Loirand et al., 2008).

    • Effects of urotensin II on functional activity of late endothelial progenitor cells

      2012, Peptides
      Citation Excerpt :

      In human, UII binds with high affinity to the orphan G-protein-coupled receptor 14 (GPR14) [18], recently referred to as UII receptor (UT) [4]. UII and its receptor are widely expressed in the cardiovascular tissues [20,21], and UII has multiple effects on the cardiovascular system, including modulation of vascular tone, myocardial contraction and heart rate [16,24]. More recently, a potential role of the UII system in the development of atherosclerosis is emerging [19].

    • Urotensin-II-stimulated expression of pro-angiogenic factors in human vascular endothelial cells

      2011, Regulatory Peptides
      Citation Excerpt :

      Urotensin-II (U-II) is a cyclic 11-amino acid (human) or 15-amino acid (rodent) peptide, originally isolated from the fish urophysis [1], which binds to a specific high-affinity G protein-coupled receptor, that has been named [2] urotensin receptor (UT). U-II and its receptor are widely expressed in the cardio-vascular system [3,4], where the peptide exerts a potent systemic vasoconstrictor and hypertensive effect [5,6], and plays an important role in cardiovascular pathophysiology (see [7]). More recently increasing evidence was provided indicating that U-II may also play a significant part in the remodeling of vascular tissues (see [8]).

    View all citing articles on Scopus
    View full text